Maple Capital Management’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.6M | Sell |
62,883
-1,702
| -3% | -$506K | 1.24% | 26 |
|
|
2025
Q4 | $17.6M | Sell |
64,585
-146
| -0.2% | -$39.7K | 1.11% | 28 |
|
|
2025
Q3 | $17.5M | Buy |
64,731
+394
| +0.6% | +$107K | 1.15% | 26 |
|
|
2025
Q2 | $17.7M | Buy |
64,337
+449
| +0.7% | +$122K | 1.21% | 28 |
|
|
2025
Q1 | $16.9M | Sell |
63,888
-442
| -0.7% | -$109K | 1.31% | 26 |
|
|
2024
Q4 | $14.9M | Sell |
64,330
-828
| -1% | -$190K | 1.1% | 28 |
|
|
2024
Q3 | $14.4M | Sell |
65,158
-273
| -0.4% | -$56.5K | 1.1% | 29 |
|
|
2024
Q2 | $12.9M | Buy |
65,431
+66
| +0.1% | +$13.6K | 1.04% | 30 |
|
|
2024
Q1 | $14.1M | Sell |
65,365
-835
| -1% | -$175K | 1.28% | 27 |
|
|
2023
Q4 | $13.9M | Buy |
66,200
+1,062
| +2% | +$227K | 1.4% | 27 |
|
|
2023
Q3 | $13M | Buy |
65,138
+215
| +0.3% | +$42.7K | 1.49% | 27 |
|
|
2023
Q2 | $12M | Buy |
64,923
+1,225
| +2% | +$226K | 1.31% | 29 |
|
|
2023
Q1 | $12.2M | Buy |
63,698
+1,263
| +2% | +$228K | 1.49% | 28 |
|
|
2022
Q4 | $10.5M | Sell |
62,435
-282
| -0.4% | -$49K | 1.39% | 28 |
|
|
2022
Q3 | $10.9M | Buy |
62,717
+1,138
| +2% | +$225K | 1.38% | 28 |
|
|
2022
Q2 | $12.6M | Buy |
61,579
+2,314
| +4% | +$490K | 1.66% | 24 |
|
|
2022
Q1 | $14.1M | Buy |
59,265
+1,410
| +2% | +$331K | 1.66% | 25 |
|
|
2021
Q4 | $13.2M | Buy |
57,855
+3,850
| +7% | +$847K | 1.44% | 28 |
|
|
2021
Q3 | $10.4M | Buy |
54,005
+448
| +0.8% | +$90.8K | 1.33% | 32 |
|
|
2021
Q2 | $11.1M | Buy |
53,557
+2,807
| +6% | +$593K | 1.34% | 32 |
|
|
2021
Q1 | $10.4M | Buy |
50,750
+1,596
| +3% | +$314K | 1.53% | 30 |
|
|
2020
Q4 | $8.95M | Sell |
49,154
-377
| -0.8% | -$64.1K | 1.38% | 32 |
|
|
2020
Q3 | $8.22M | Buy |
49,531
+999
| +2% | +$168K | 1.33% | 33 |
|
|
2020
Q2 | $7.89M | Buy |
48,532
+1,207
| +3% | +$216K | 1.55% | 30 |
|
|
2020
Q1 | $8.18M | Buy |
47,325
+1,775
| +4% | +$353K | 2.04% | 22 |
|
|
2019
Q4 | $9.14M | Buy |
45,550
+2,915
| +7% | +$598K | 1.77% | 25 |
|
|
2019
Q3 | $9.01M | Buy |
42,635
+4,610
| +12% | +$963K | 1.94% | 25 |
|
|
2019
Q2 | $7.38M | Buy |
38,025
+3,649
| +11% | +$673K | 1.66% | 30 |
|
|
2019
Q1 | $5.66M | Buy |
34,376
+3,049
| +10% | +$539K | 1.33% | 31 |
|
|
2018
Q4 | $5.89M | Buy |
31,327
+1,436
| +5% | +$265K | 1.52% | 31 |
|
|
2018
Q3 | $5.09M | Buy |
+29,891
| New | +$5.03M | 1.15% | 35 |
|
Other funds holding CME
VCM
VPM
Maple Capital Management's CME Position: Q1 2026 in Review
Maple Capital Management reduced its CME Group (CME) stake by 2.6% in Q1 2026, selling an estimated $506K and leaving 62,883 shares worth $18.6M. The position accounts for 1.24% of the portfolio, ranked #26.
Maple Capital Management first reported a position in CME in Q3 2018 and has held it in 31 quarters since. 1,791 funds tracked by Wall St. Rank hold CME as of Q1 2026.
- Maple Capital Management held 62,883 shares of CME Group worth $18.6M as of Q1 2026.
- Maple Capital Management sold 1,702 CME Group shares in Q1 2026, an estimated $506K.
- CME Group made up 1.24% of Maple Capital Management's portfolio in Q1 2026, its #26 holding.
- Maple Capital Management first reported a position in CME Group in Q3 2018 and has held it in 31 quarters since.
- 1,791 funds tracked by Wall St. Rank held CME Group as of Q1 2026.
Based on Maple Capital Management's 13F filing for Q1 2026, filed 8 May 2026.